Biomedical Engineering Reference
In-Depth Information
factor-alpha inhibitor expressed from a self-contained doxy-
cycline regulated plasmid. Arthritis Res. Ther. 6, R103-113.
24. Xiong ZF, Hu S, Wang ZH. (2010) Role of a latent soluble
TNF receptor type I (hsTNFRI) fusion protein in targeted
treatment of endometriosis. Zhonghua Yi Xue Za Zhi 90,
768-771.
25. Spuijbroek MD, Dunselman GA, Menheere PP, Evers JL.
(1992) Early endometriosis invades the extracellular matrix.
Fertil. Steril. 58, 929-933.
26. Sillem M, Prifti S, Koch A, Neher M, Jauckus J, Runnebaum
B. (2001) Regulation of matrix metalloproteinases and their
inhibitors in uterine endometrial cells of patients with and
without endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol.
95, 167-174.
27. Neve R, Kissonerghis M, Clark J, Feldmann M, Chernajovsky
Y. (1996) Expression of an efficient small molecular weight
tumour necrosis factor/lymphotoxin antagonist. Cytokine 8,
365-370.
28. Moren A, Olofsson A, Stenman G, Sahlin P, Kanzaki T,
Claesson-Welsh L, et al. (1994) Identification and
characterization of LTBP-2, a novel latent transforming
growth factor-beta-binding protein. J. Biol. Chem. 269,
32469-32478.
29. Olofsson A, Ichijo H, Moren A, ten Dijke P, Miyazono K,
Heldin CH. (1995) Efficient association of an amino-termi-
nally extended form of human latent transforming growth
factor-beta binding protein with the extracellular matrix. J.
Biol. Chem. 270, 31294-31297.
30. Saharinen J, Keski-Oja J. (2000) Specific sequence motif of
8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a
hydrophobic interaction surface for binding of small latent
TGF-beta. Mol. Biol. Cell 11, 2691-2704.
31. Wakefield LM, Smith DM, Broz S, Jackson M, Levinson AD,
Sporn MB. (1989) Recombinant TGF-beta 1 is synthesized as
a two-component latent complex that shares some structural
features with the native platelet latent TGF-beta 1 complex.
Growth Factors 1, 203-218.
32. Brunner AM, Marquardt H, Malacko AR, Lioubin MN,
Purchio AF. (1989) Site-directed mutagenesis of cysteine
residues in the pro region of the transforming growth factor
beta 1 precursor. Expression and characterization of mutant
proteins. J. Biol. Chem. 264, 13660-13664.
33. Leavitt R, Schlesinger S, Kornfeld S. (1977) Impaired intra-
cellular migration and altered solubility of nonglycosylated
glycoproteins of vesicular stomatitis virus and Sindbis virus.
J. Biol. Chem. 252, 9018-9023.
34. Machamer CE, Rose JK. (1988) Influence of new
glycosylation sites on expression of the vesicular stomatitis
virus G protein at the plasma membrane. J. Biol. Chem. 263,
5948-5954.
35. Dorner AJ, Bole DG, Kaufman RJ. (1987) The relationship of
N-linked glycosylation and heavy chain-binding protein asso-
ciation with the secretion of glycoproteins. J. Cell Biol. 105,
2665-2674.
36. Sha X, Brunner AM, Purchio AF, Gentry LE. (1989) Trans-
forming growth factor beta 1: importance of glycosylation
and acidic proteases for processing and secretion. Mol.
Endocrinol. 3, 1090-1098.
37. Lopez AR, Cook J, Deininger PL, Derynck R. (1992) Domi-
nant negative mutants of transforming growth factor-beta 1
inhibit the secretion of different transforming growth factor-
beta isoforms. Mol. Cell Biol. 12, 1674-1679.
38. Brunner AM, Lioubin MN, Marquardt H, Malacko AR, Wang
WC, Shapiro RA, et al. (1992) Site-directed mutagenesis of
glycosylation sites in the transforming growth factor-beta 1
(TGF beta 1) and TGF beta 2 (414) precursors and of cysteine
residues within mature TGF beta 1: effects on secretion and
bioactivity. Mol. Endocrinol. 6, 1691-1700.
39. Sinclair AM, Elliott S. (2005) Glycoengineering: the effect of
glycosylation on the properties of therapeutic proteins. J.
Pharm. Sci. 94, 1626-1635.
40. Werner RG, Kopp K, Schlueter M. (2007) Glycosylation of
therapeutic proteins in different production systems. Acta
Paediatr. Suppl. 96, 17-22.
41. Brunner AM, Gentry LE, Cooper JA, Purchio AF. (1988)
Recombinant type 1 transforming growth factor beta precur-
sor produced in Chinese hamster ovary cells is glycosylated
and phosphorylated. Mol. Cell Biol. 8, 2229-2232.
42. Purchio AF, Cooper JA, Brunner AM, Lioubin MN, Gentry
LE, Kovacina KS, (1988) Identification of mannose 6-phos-
phate in two asparagine-linked sugar chains of recombinant
transforming growth factor-beta 1 precursor. J. Biol. Chem.
263, 14211-14215.
43. Wakefield LM, Winokur TS, Hollands RS, Christopherson K,
Levinson AD, Sporn MB. (1990) Recombinant latent trans-
forming growth factor beta 1 has a longer plasma half-life in
rats than active transforming growth factor beta 1, and a
different tissue distribution. J. Clin. Invest. 86, 1976-1984.
44. Miyazono K, Heldin CH. (1989) Role for carbohydrate
structures in TGF-beta 1 latency. Nature 338, 158-160.
45. Yang Y, Dignam JD, Gentry LE. (1997) Role of carbohydrate
structures in the binding of beta1-latency-associated peptide
to ligands. Biochemistry 36, 11923-11932.
46. Chitlaru T, Kronman C, Zeevi M, Kam M, Harel A, Orden-
tlich A, et al. (1998) Modulation of circulatory residence of
recombinant acetylcholinesterase through biochemical or
genetic manipulation of sialylation levels. Biochem. J. 336,
647-658.
47. Poser CM, Brinar VV. (2004) The nature of multiple sclerosis.
Clin. Neurol. Neurosurg. 106, 159-171.
48. Arnason BG. (1999) Immunologic therapy of multiple scle-
rosis. Annu. Rev. Med. 50, 291-302.
49. Hohlfeld R, Wekerle H. (2001) Immunological update on
multiple sclerosis. Curr. Opin. Neurol. 14, 299-304.
50. Rott O, Fleischer B, Cash E. (1994) Interleukin-10 prevents
experimental allergic encephalomyelitis in rats. Eur. J.
Immunol. 24, 1434-1440.
51. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA,
Kuchroo VK. (1998) IL-10 is critical in the regulation of
autoimmune encephalomyelitis as demonstrated by studies of
IL-10- and IL-4-deficient and transgenic mice. J. Immunol.
161, 3299-3306.
Search WWH ::
Custom Search